Orexigen Therapeutics (OREX) Receiving Somewhat Positive News Coverage, Report Finds

Headlines about Orexigen Therapeutics (NASDAQ:OREX) have trended somewhat positive recently, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Orexigen Therapeutics earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.0619384085862 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the news stories that may have impacted Accern’s scoring:

Shares of Orexigen Therapeutics (OREX) traded up $0.01 on Friday, hitting $1.17. 1,081,608 shares of the stock traded hands, compared to its average volume of 275,154. Orexigen Therapeutics has a 12 month low of $1.14 and a 12 month high of $5.70. The company has a market capitalization of $18.05, a PE ratio of -0.12 and a beta of 2.31. The company has a debt-to-equity ratio of -2.75, a current ratio of 2.00 and a quick ratio of 1.71.

Orexigen Therapeutics (NASDAQ:OREX) last announced its earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.35) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.13) by $0.78. The company had revenue of $18.90 million for the quarter, compared to analysts’ expectations of $24.20 million. Orexigen Therapeutics had a negative net margin of 192.65% and a negative return on equity of 824.15%. The business’s revenue for the quarter was up 170.0% on a year-over-year basis. During the same period last year, the firm earned $1.12 earnings per share. sell-side analysts forecast that Orexigen Therapeutics will post -10.08 EPS for the current year.

Separately, Zacks Investment Research raised shares of Orexigen Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday.

ILLEGAL ACTIVITY NOTICE: “Orexigen Therapeutics (OREX) Receiving Somewhat Positive News Coverage, Report Finds” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://sportsperspectives.com/2018/01/19/orexigen-therapeutics-orex-receiving-somewhat-positive-news-coverage-report-finds.html.

Orexigen Therapeutics Company Profile

Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.

Insider Buying and Selling by Quarter for Orexigen Therapeutics (NASDAQ:OREX)

Receive News & Ratings for Orexigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply